NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Goldman to Buy. Company trades at a reasonable valuation and is showing strong organic asset growth.
( AYE) upgraded at Credit Suisse to Outperform from Neutral. Best leverage to likely EPA policy. Shares now seen reaching $28, up from $23.
upgraded at Soleil from Hold to Buy. $116 price target. Company should benefit from higher corn and lower natural gas prices.
rated new Positive at Susquehanna. $52 price target. Company should be able to exceed 20% annual earnings growth through 2012.
upgraded at UBS from Neutral to Buy. $36 price target. Estimates also boosted, as the new management team has the company back on the right track.
downgraded at Credit Suisse to Neutral from Outperform on nuclear power plant issues, strategic direction, and lower comparable gearing. Price target sunk to $81 from $86.
upgraded at Piper from Neutral to Overweight. $77 price target. Partner trial performed well, which could mean higher sales down the road.
price target boosted at Barclays to $65 from $60 on positive drug data. Maintain Overweight rating.
upgraded at Credit Suisse to Outperform from Neutral. EPA policy likely, buy clean plants in dirty markets. Price target lifted to $43 from $41.50.
downgraded at Morgan Stanley from Overweight to Equal-weight. Estimates also cut, because of higher expected spending on new product launches.
rated new Hold at Citigroup. $19 price target. Stock is already down 38% year-to-date, but natural gas prices will likely remain constrained.
rated new Positive at Susquehanna. $76 price target. Company should benefit from surging DAP prices.
upgraded at BMO from Market Perform to Outperform. $16 price target. GPU share losses should slow and Tegra appears to finally be gaining traction.
rated new Neutral at Susquehanna. $150 price target. Earnings should benefit from a volume recovery and higher prices, but the BHP offer has already placed a premium on the stock.
downgraded at Goldman from Neutral to Sell. Valuation call, based on a $41 price target. Company also faces tough sales comparisons and rising marketing costs.
upgraded at Morgan Stanley to Overweight. $27 price target. Company can generate strong earning and will likely pay down some of its debt.
STOCK COMMENTS / EPS CHANGES
estimates, target raised at Oppenheimer. Shares of AKAM now seen reaching $58. Estimates also increased, given improving online video trends. Outperform rating.
Bed Bath & Beyond
numbers upped at Citigroup. BBBY estimates were boosted through 2012. Company raised its forward guidance. Buy rating and new $59 price target.
Bed Bath & Beyond
estimates tweaked at Credit Suisse. BBBY 2011 and 2012 EPS estimates raised to $2.77 and $3.00, respectively, as the company reported a very solid quarter. Maintain Neutral rating and $50 price target.
Bed Bath & Beyond
target, estimates lifted at Barclays. BBBY price target raised by a dollar to $47 on strong 2Q10 results. 2011 and 2012 EPS estimates tweaked higher to $2.77 and $3.03, respectively. Maintain Equal Weight rating.
estimates, target increased at BofA/Merrill. DE estimates were raised through 2012. International sales visibility is improving. Buy rating and new $85 price target.
numbers cut at Morgan Stanley. Shares of DGX now seen reaching $58. Estimates also reduced, to match the company's new guidance. Underweight rating.
estimates increased at Morgan Stanley through 2012. Company will likely take funds from asset sales to buy back stock and invest in oil-rich areas. Overweight rating and $74 price target.
numbers boosted at Goldman. Shares of EMN now seen reaching $84. Estimates also upped, given improving selling prices and volumes. Buy rating.
estimates increased at Goldman through 2012. Company is seeing more of a benefit from fuel surcharges. Neutral rating and $95 price target.
estimates cut at Keybanc through 2011. Company is seeing lower sales and margins. Buy rating and $29 price target.
estimates lowered at UBS through 2011. Market trends suggest further pricing pressure. Buy rating and $25 price target.
target boosted at BofA/Merrill. Shares of INTU now seen reaching $49. Cloud revenue is growing. Buy rating.
target, estimates boosted at Barclays. JASO price target raised to $8 from $6 as industry checks indicate cell fundamentals will remain strong in Dec. 2010 and 2011 EPS estimates lifted to $1.25 and $0.95, respectively. Maintain Equal Weight rating.
cut from Conviction Sell List at Goldman. Stock has underperformed the market by 20% over the past year, but increased hiring could lead to future growth. $22 price target.
estimates, target upped at Goldman. KMX estimates were boosted through 2012. Company is realizing higher incremental profits. Neutral rating and new $27 price target.
target, estimates lifted at Credit Suisse. KMX price target jumped to $28 from $23 on excellent 2Q10 results. Estimates raised through 2013. Maintain Neutral rating.
added to Conviction Buy List at Goldman. Earnings growth should re-accelerate in the second half of 2010. $26 price target.
price target higher at Citi. PGN price target lifted to $45 from $40 as eventful 2011 calendar could see many catalysts, Citigroup said. Maintain Hold rating.
target, estimate increased at Barclays. PM price target improved to $59 from $54. PM is the most leveraged to currency movement. 2010 and 2011 EPS estimates raised to $3.80 and $4.25, respectively. Maintain Overweight rating.
estimates, target raised at Goldman. Shares of RHT now seen reaching $37. Estimates also increased, given improved bookings growth. Neutral rating.
price target raised at Barclays. RHT price target increased to $36 from $33 following a beat and raise quarter. 20% billings growth. Maintain Equal Weight rating.
target boosted at Morgan Stanley to $35. Demand for ultra-deepwater rigs is rebounding. Overweight rating.
target raised at ThinkEquity to $21. Expect further clinical success from Relovair. Buy rating.
target boosted at Citigroup. Shares of XL now seen reaching $25. Stock trades at just 0.7 times book value and the company's portfolio is improving. Buy rating.
This article was written by a staff member of TheStreet.